Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 19;12:794638. doi: 10.3389/fimmu.2021.794638

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Chang, Wu, Webb, Tiwary, Hughes, Reed, Hwang, Waytashek, Boyle, Pessoa, Sylwester, Morrow, Belica, Fischer, Kelly, Pourhassan, Bochart, Smedley, Recknor, Hansen and Sacha

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

CCR5 receptor occupancy assay overview. (A) Flow cytometry diagram showing the interactions between anti-CCR5, Leronlimab, Leronlimab-PacBlu (PB), and anti-human IgG4 for the two equations using a CCR5 unoccupied (top) and fully occupied (bottom) scenario. (B) Equations for calculating CCR5 RO. (C) Representative flow cytometry plots displaying the different components needed to calculate for the two equations using a rhesus macaque that received a single 50 mg/kg SC Leronlimab injection. Equation 1 used %IgG4+ events within CD45+, singlet, live, CD3+, CD4+/CD8-, and CCR5+ events. Equation 2 used %IgG4+ and Leronlimab-PB+ events within CD45+, singlet, live, CD3+, CD4+/CD8-, and CCR5+ events. Table on the right shows the calculated CCR5 RO calculated by the two equations at study weeks 0, 4, and 14 post single Leronlimab injection. (D) Left Y-axis is for CCR5 RO by Leronlimab on peripheral blood CD4+CCR5+ T cells calculated by equation 1 (solid blue circle) and equation 2 (open blue square). Right Y-axis is for the longitudinal plasma concentration (solid black triangle) in blood samples from the treated macaque.